Enliven Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ELVN Nasdaq 2836 www.enliventherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enliven Therapeutics, Inc.

Enliven Therapeutics to Present at Upcoming Investor Conferences - May 21st, 2026 2:05 pm
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% - May 13th, 2026 3:06 pm
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML - May 12th, 2026 7:53 am
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026? - May 10th, 2026 5:13 pm
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - May 7th, 2026 2:05 pm
Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market - Apr 17th, 2026 5:15 am
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho - Apr 6th, 2026 3:09 pm
Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum - Mar 29th, 2026 11:05 pm
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million - Mar 28th, 2026 10:46 am
Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’ - Mar 25th, 2026 6:46 pm
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - Mar 3rd, 2026 2:05 pm
Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Feb 25th, 2026 2:05 pm
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k - Jan 31st, 2026 11:18 pm
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging Phase 1b ENABLE Trial Data - Jan 8th, 2026 6:13 pm
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones - Jan 8th, 2026 7:00 am
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - Jan 7th, 2026 7:00 am
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - Dec 11th, 2025 2:21 pm
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - Dec 11th, 2025 7:00 am
Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress - Dec 9th, 2025 9:10 am
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - Dec 3rd, 2025 7:55 am